{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0","upperLimit":"11.3","value":"4.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"16"}],"units":"Participants"}],"description":"Time is calculated from the diagnosis to the last follow-up date if no disease progression , or the date of disease progression after the last treatment cycle of the study drugs","dispersionType":"95% Confidence Interval","groups":[{"description":"trientine dihydrochloride PO daily \\[through dose level 1 (300mg/day) to level 6 (1800mg/day)\\] plus pegylated liposomal doxorubicin IV D1 plus carboplatin IV D1\n\ntrientine dihydrochloride: trientine dihydrochloride 300MG/CAPSUE PO daily \\[through dose level 1 (300mg/day) to level 6 (1800mg/day)\\]\n\npegylated liposomal doxorubicin: pegylated liposomal doxorubicin 40mg/m2 IV D1\n\ncarboplatin: carboplatin AUC 4 IV D1","id":"OG000","title":"Trientine With Chemotherapy"}],"paramType":"MEDIAN","populationDescription":"According the protocol for this secondary outcome, data collected from participants receiving different dose levels were intended to be combined and analyzed as a single group.","reportingStatus":"POSTED","timeFrame":"36 months","title":"Progression-free Survival","type":"SECONDARY","unitOfMeasure":"months"}